enzalutamide after docetaxel for mcrpc: evaluation by the italian named patient program
Published 5 years ago • 127 plays • Length 1:57Download video MP4
Download video MP3
Similar videos
-
3:44
updates from the cheiron study: docetaxel plus enzalutamide for mcrpc
-
1:10
preside: investigating continued treatment with enzalutamide in pc following disease progression
-
1:37
dr. caffo discusses enzalutamide/docetaxel combination in frontline mcrpc
-
0:55
post-progression therapies in patients with mcrpc progressing after docetaxel
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
2:26
caspar: the addition of rucaparib to enzalutamide for the treatment of mcrpc
-
14:30
mcrpc care: reducing progression risk by combining enzalutamide and talazoparib
-
2:10
current standards for first-line metastatic hormone-sensitive prostate cancer
-
1:21
keynote-921: pembrolizumab plus docetaxel in chemotherapy-naïve mcrpc
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
4:17
cheiron study: docetaxel plus enzalutamide versus docetaxel as first-line chemotherapy for patie...
-
1:44
talapro-2: exposure-safety of talazoparib enzalutamide in mcrpc
-
2:18
arches: enzalutamide plus adt in mhspc subgroups
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
4:35
support for continuing enzalutamide after mcrpc progression | axel merseburger
-
1:25
procaid: capivasertib plus docetaxel and prednisolone chemotherapy for the treatment of mcrpc
-
2:06
mcrpc: cabazitaxel re-challenge
-
0:46
ctc hoxb13 rna in mcrpc: abiraterone/enzalutamide impact
-
2:59
triton3 interim os results demonstrate superiority of rucaparib over docetaxel for mcrpc